Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia

被引:23
作者
Baker, KS
Bostrom, B
DeFor, T
Ramsay, NKC
Woods, WG
Blazar, BR
机构
[1] Univ Minnesota, Ctr Canc, Pediat Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Pediat, Div Hematol Oncol & Stem Cell Transplantat, Minneapolis, MN 55455 USA
[3] Childrens Hosp, Minneapolis, MN USA
[4] S Carolina Canc Ctr, Columbia, SC USA
关键词
busulfan; pharmacokinetics; acute myelogenous leukemia;
D O I
10.1038/sj.bmt.1702590
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The purpose of this study was to evaluate the influence of busulfan (BU) pharmacokinetics on survival, grades II-IV acute graft-versus-host disease (GVHD), non-relapse mortality (NRM) and relapse in a group composed of 45 children (<18 years) and seven adults with acute myeloid leukemia (AR IL) in first complete remission and undergoing hematopoietic stem cell transplantation (SCT), Fifty-two patients underwent autologous (n = 25) or allogeneic (n = 27) SCT, The median age was 8.9 years (range 0.6-53 years). Conditioning therapy consisted of BU and cyclophosphamide, Improved disease-free survival was found in those patients with a steady-state concentration of BU (CssBU) below the median (<578 mg/ml, P = 0.05), and the same trend was noted for overall survival (P = 0.07), This was secondary to a higher incidence of NRM in the group of patients with CssBU above the median (P = 0.06), There was no significant correlation with CssBU and relapse (P = 0.31), No association between CssBU and GVHD was found in allogeneic patients (P = 0.30), Relapse was evaluated among the subgroups of age (< or > 10 years) and transplant type (allogeneic or autologous) with no statistically significant association observed among these factors, Multiple regression analysis for relapse revealed no significant correlation with CssBU above or below the median, age, or transplant type. In this study, CssBU below the median did not correlate with an inferior outcome for patients with AML, Pharmacokinetic dosing of BU may be important for prevention of NRM: but does not appear to influence the risk of relapse in this largely pediatric population with AML.
引用
收藏
页码:607 / 614
页数:8
相关论文
共 40 条
[1]   Growth after bone marrow transplantation in young children conditioned with chemotherapy alone [J].
Adan, L ;
deLanversin, ML ;
Thalassinos, C ;
Souberbielle, JC ;
Fischer, A ;
Brauner, R .
BONE MARROW TRANSPLANTATION, 1997, 19 (03) :253-256
[2]  
Andersson BS, 1999, BLOOD, V94, p167A
[3]   PRETRANSPLANT CONDITIONING WITH BUSULFAN (MYLERAN) AND CYCLOPHOSPHAMIDE FOR NONMALIGNANT DISEASES - ASSESSMENT OF ENGRAFTMENT FOLLOWING HISTOCOMPATIBLE ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
BLAZAR, BR ;
RAMSAY, NKC ;
KERSEY, JH ;
KRIVIT, W ;
ARTHUR, DC ;
FILIPOVICH, AH .
TRANSPLANTATION, 1985, 39 (06) :597-603
[4]   BUSULFAN [J].
BUGGIA, I ;
LOCATELLI, F ;
REGAZZI, MB ;
ZECCA, M .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (09) :1055-1062
[5]  
Buggia I, 1996, ANTICANCER RES, V16, P2083
[6]   An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children [J].
Chattergoon, DS ;
Saunders, EF ;
Klein, J ;
Calderwood, S ;
Doyle, J ;
Freedman, MH ;
Koren, G .
BONE MARROW TRANSPLANTATION, 1997, 20 (05) :347-354
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]   Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia [J].
Davies, SM ;
Ramsay, NKC ;
Klein, JP ;
Weisdorf, DJ ;
Bolwell, B ;
Cahn, JY ;
Camitta, BM ;
Gale, RP ;
Giralt, S ;
Heilmann, C ;
Henslee-Downey, PJ ;
Herzig, RH ;
Hutchinson, R ;
Keating, A ;
Lazarus, HM ;
Milone, GA ;
Neudorf, S ;
Perez, WS ;
Powles, RL ;
Prentice, HG ;
Schiller, G ;
Socié, G ;
Vowels, M ;
Wiley, J ;
Yeager, A ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) :340-347
[9]  
DEEG HJ, 1984, ANNU REV MED, V35, P11, DOI 10.1146/annurev.med.35.1.11
[10]  
Demirer T, 1996, BONE MARROW TRANSPL, V17, P341